Innovations: Randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC)

Autor:	Michael Thomas, Juergen R. Fischer, Philipp A. Schnabel, Christian Grah, Stefan Andreas, Dirk Behringer, Niels Reinmuth, R. Heine, Alexander Reuss, Monika Serke, Christian Witt, Cornelius Kortsik, M. Schroeder, Jens Kollmeier, Ernst Müller, M. Schenk, Martin Wolf, Thomas Acker, L. J. Müller, M. von Eiff
Rok vydání:	2011
Předmět:	Oncology Cisplatin Cancer Research medicine.medical_specialty Pathology Bevacizumab business.industry non-small cell lung cancer (NSCLC) Kinase inhibition medicine.disease Gemcitabine First line treatment Internal medicine medicine Erlotinib business Clin oncol medicine.drug
Zdroj:	Journal of Clinical Oncology. 29:7504-7504
ISSN:	1527-7755 0732-183X
Popis:	7504 Background: Combining EGFR kinase inhibition (E) with an anti-VEGF strategy (B) showed promising activity (RR 20%; PFS 6.2 months) in recurrent NS-NSCLC (J Clin Oncol (2005) 23: 2544). To asse...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4861c7604f45805bd7c9d70768997af9 https://doi.org/10.1200/jco.2011.29.15_suppl.7504 Zobrazit plný text záznamu